Wall Street brokerages predict that Galapagos NV (NASDAQ:GLPG) will post sales of $115.36 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Galapagos’ earnings. The highest sales estimate is $172.72 million and the lowest is $58.00 million. The firm is expected to report its next earnings report on Thursday, March 24th.
According to Zacks, analysts expect that Galapagos will report full year sales of $549.41 million for the current financial year, with estimates ranging from $468.64 million to $597.59 million. For the next year, analysts anticipate that the firm will report sales of $542.03 million, with estimates ranging from $259.84 million to $687.53 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Galapagos.
Galapagos (NASDAQ:GLPG) last released its quarterly earnings data on Friday, November 5th. The biotechnology company reported ($1.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.67) by $0.50. Galapagos had a negative net margin of 36.28% and a negative return on equity of 7.81%. The business had revenue of $75.69 million during the quarter, compared to analyst estimates of $95.17 million.
A number of hedge funds and other institutional investors have recently bought and sold shares of GLPG. OLD Mission Capital LLC increased its position in Galapagos by 290.1% during the 3rd quarter. OLD Mission Capital LLC now owns 113,719 shares of the biotechnology company’s stock valued at $16,138,000 after purchasing an additional 84,569 shares during the period. Geode Capital Management LLC increased its position in Galapagos by 4.8% during the 1st quarter. Geode Capital Management LLC now owns 4,820 shares of the biotechnology company’s stock valued at $371,000 after purchasing an additional 222 shares during the period. Bank of New York Mellon Corp grew its position in shares of Galapagos by 6.9% in the 1st quarter. Bank of New York Mellon Corp now owns 8,327 shares of the biotechnology company’s stock worth $642,000 after buying an additional 541 shares during the last quarter. HRT Financial LP purchased a new position in shares of Galapagos in the 1st quarter worth approximately $886,000. Finally, Royal Bank of Canada grew its position in shares of Galapagos by 10.3% in the 1st quarter. Royal Bank of Canada now owns 37,445 shares of the biotechnology company’s stock worth $2,887,000 after buying an additional 3,508 shares during the last quarter. 11.17% of the stock is currently owned by institutional investors and hedge funds.
GLPG stock traded up $1.16 during trading on Thursday, hitting $49.62. 131,250 shares of the company’s stock traded hands, compared to its average volume of 281,026. Galapagos has a 52 week low of $47.87 and a 52 week high of $129.03. The business has a fifty day simple moving average of $52.57 and a 200 day simple moving average of $61.44.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Further Reading: What are convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.